Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: Potential role of other positron emission tomography radiotracers

Seminars in Nuclear Medicine

Volumn 42, Issue 4, 2012, Pages 247-254

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; LEVODOPA; PASIREOTIDE TETRAXETAN GALLIUM GA 68; TRACER;

CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; GASTROINTESTINAL TUMOR; HUMAN; ISOTOPE LABELING; LIVER CELL CARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FLUORODEOXYGLUCOSE F18; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; STOMACH NEOPLASMS;

EID: 84861960639     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.02.001     Document Type: Review

References (103)

1. Basu S, Alavi A: Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care. Nucl Med Rev Cent Eat Eur 2009;12:1-13
2. Kwee TC, Basu S, Saboury B, et al: A new dimension of FDG-PET interpretation: Assessment of tumor biology. Eur J Nucl Med Mol Imaging 2011;38:1158-1170
3. Arnold R, Göke R, Wied M, et al: Chapter 15: Neuroendocrine gastro-entero-pancreatic (GEP) tumors, in Scheppach W, Bresalier RS, Tytgat GNJ, (eds): Gastrointestinal and Liver Tumors. Berlin, Springer, 2003, pp 195-233
4. Oberg K, Castellano D: Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011;30(suppl 1):3-7
5. Basu S, Kumar R, Rubello D, et al: PET imaging in neuroendocrine tumors: Current status and future prospects. Minerva Endocrinol 2008;33:257-275
6. Ambrosini V, Tomassetti P, Franchi R, et al: Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54:16-23
7. Jadvar H, Segall GM: False-negative fluorine-18 FDG-PET in metastatic carcinoid. J Nucl Med 1997;38:1382-1383 (Pubitemid 27386194)
8. Pasquali C, Rubello D, Sperti C, et al: Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-592 (Pubitemid 28215437)
9. Adams S, Baum R, Rink T, et al: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79-83 (Pubitemid 28107907)
10. Eriksson B, Bergström M, Orlefors H, et al: Use of PET in neuroendocrine tumors: In vivo applications and in vitro studies. Q J Nucl Med 2000;44:68-76 (Pubitemid 30325955)
11. Carrasquillo JA, Chen CC: Molecular imaging of neuroendocrine tumors. Semin Oncol 2010;37:662-679
12. Wong KK, Arabi M, Zerizer I, et al: Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: Fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun 2011;32:764-781
13. Khan S, Lloyd C, Szyszko T, et al: PET imaging in endocrine tumors. Minerva Endocrinol 2008;33:41-52
14. Giammarile F, Billotey C, Lombard-Bohas C, et al: 18F-FLT and 18FFDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumors. Nucl Med Commun 2011;32:91-97
15. Binderup T, Knigge U, Loft A, et al: Functional imaging of neuroendocrine tumors: A head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG-PET. J Nucl Med 2010;51:704-712
16. Binderup T, Knigge U, Loft A, et al: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-985
17. Sundin A, Eriksson B, Bergström M, et al: PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004;1014:246-257 (Pubitemid 38594812)
18. Li S, Beheshti M: The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 2005;5:139-148 (Pubitemid 40488599)
19. Fanti S, Ambrosini V, Tomassetti P, et al: Evaluation of unusual neuroendocrine tumors by means of 68Ga-dota-NOC PET. Biomed Pharmacother 2008;62:667-671
20. Khan M, Combs C, Brunt E, et al: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797 (Pubitemid 30262739)
21. Al-Nahhas A, Win Z, Szyszko T, et al: Gallium-68 PET: A new frontier in receptor cancer imaging. Anticancer Res 2007;27:4087-4094
22. Goldsmith SJ: Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol 2009;5:75-84
23. Kwekkeboom DJ, Kam BL, van Essen M, et al: Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-R73
24. Breeman WA, de Blois E, Sze Chan H, et al: (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;41:314-321
25. Neels OC, Koopmans KP, Jager PL, et al: Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cell. Cancer Res 2008; 68:7183-7190
26. Minn H, Kauhanen S, Seppänen M, et al: 18F-FDOPA: A multiple-target molecule. J Nucl Med 2009;50:1915-1918
27. Montravers F, Kerrou K, Nataf V, et al: Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94:1295-1301
28. Montravers F, Grahek D, Kerrou K, et al: Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47:1455-1462 (Pubitemid 47544931)
29. Tessonnier L, Sebag F, Ghander C, et al: Limited value of 18F-FDOPA to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 2010;95:303-307
30. Becherer A, Szabó M, Karanikas G, et al: Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J Nucl Med 2004;45:1161-1167 (Pubitemid 47611661)
31. Kaemmerer D, Peter L, Lupp A, et al: Molecular imaging with 68Ga- SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2011;38:1659-1668
32. Ambrosini V, Nanni C, Zompatori M, et al: 68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2010;37:722-727
33. Ambrosini V, Tomassetti P, Castellucci P, et al: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastroentero-pancreatic and lung neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:1431-1438
34. Ambrosini V, Campana D, Bodei L, et al: 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-673
35. Naswa N, Sharma P, Kumar A, et al: Gallium-68-dota-NOC PET/CT of patients with gastroeneteropancreatic neuroendocrine tumors: A prospective single-center study. Am J Roentgenol 2011;197:1221-28
36. Krausz Y, Rubinstein R, Appelbaum L, et al: Ga-68 DOTA-NOC uptake in the pancreas: Pathological and physiological patterns. Clin Nucl Med 2012;37:57-62
37. Kumar R, Sharma P, Garg P, et al: Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumors. Eur Radiol 2011;21:2408-2416
38. Versari A, Camellini L, Carlinfante G, et al: Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: A single-centre retrospective study. Clin Nucl Med 2010;35:321-328
39. Gabriel M, Oberauer A, Dobrozemsky G, et al: 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-1434
40. Putzer D, Gabriel M, Kendler D, et al: Comparison of 68Ga-DOTATyr(3)- octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54:68-75
41. Kayani I, Bomanji J, Groves A, et al: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:24447-24455
42. Cwikla JB, Nasierowska-Guttmejer A, Jeziorski KG, et al: Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin-Single NET center experience in Poland. Neuro Endocrinol Lett 2007;28:789-800
43. Beauregard JM, Hofman MS, Kong G, et al: The tumor sink effect on the iodistribution of 68Ga-DOTA-octreotate: Implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2012;39:50-56
44. Al-Ibraheem A, Bundschuh RA, Notni J, et al: Focal uptake of 68Ga-DOTATOC in the pancreas: Pathological or physiological correlate in patients with neuroendocrine tumors? Eur J Nucl Med Mol Imaging 2011;38:2005-2013
45. Gabriel M, Decristoforo C, Kendler D, et al: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518 (Pubitemid 47571404)
46. Hofmann M, Maecke H, Börner R, et al: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 2001;28:1751-1757
47. Poeppel TD, Binse I, Peterson S, et al: 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;12:1864-1870
48. Hanin FX, Pauwels S, Bol A, et al: Tumor uptake of 68Ga-DOTATyr3- octrotate: Animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model. Nucl Med Biol 2010;37:157-165
49. Haug AR, Rominger A, Mustafa M, et al: Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011;52:1679-1683
50. Schreiter NF, Brenner W, Nogami M, et al: Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2012;39:72-82
51. Kumar V, Fausto N, Abbas A (eds): Robbins and Cotran Pathologic Basis of Disease (ed 7). Philadelphia, PA: Sauders, 2003, pp 914-917
52. Paudyal B, Paudyal P, Oriuchi N, et al: Clinical implication of glucose transport and metabolism evaluated by 18F-FDG-PET in hepatocellular carcinoma. Int J Oncol 2008;33:1047-1054
53. Paudyal B, Oriuchi N, Paudyal P, et al: Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008;22:83-86 (Pubitemid 351207655)
54. Seo S, Hatano E, Higashi T, et al: P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 2009;34:1303-1312
55. Yu Kuang, Schomisch SJ, Chandramouli V, et al: Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol 2006;143:225-231
56. Trojan J, Schroeder O, Raedle J, et al: Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319
57. Kitamura K, Hatano E, Higashi T, et al: Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 2011;55:846-857
58. Ahn SG, Kim SH, Jeon TJ, et al: The role of preoperative 18F-fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinoma. J Gastrointest Surg 2011;15:2044-2052
59. Ahn KJ, Hwang HS, Park JH, et al: Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J Nucl Med 2009;50:1525-1532
60. Salem N, MacLennan GT, Kuang Y, et al: Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol 2007;9:135-143 (Pubitemid 46705707)
61. Lee JD, Yun M, Lee JM, et al: Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluordeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-1630 (Pubitemid 40104608)
62. Wudel LJ Jr, Delbeke D, Morris D, et al: The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Ann Surg 2003;69:117-124
63. Torizuka T, Tamaki N, Inokuma T, et al: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817
64. Seo S, Hatano E, Higashi T, et al: Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13(2 Pt 1):427-433 (Pubitemid 46225346)
65. Bernstine H, Braun M, Yefremov N, et al: FDG-PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma. Radiology 2011;260:503-510
66. Wolfort RM, Papillion PW, Turnage RH, et al: Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg 2010;95:67-75
67. Kitamura K, Hatano E, Higashi T, et al: Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 2012;19:156-162
68. Kim Y, Lee K, Cho S, et al: Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transplant 2010;16:767-772
69. Kim B, Kang W, Kim J, et al: 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011 Apr 5 [Epub ahead of print]
70. Kornberg A, Freesmeyer M, Bärthel E, et al: 18F-FDG uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592-600
71. Shiomi S, Nishiguchi S, Ishizu H, et al: Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-1880
72. Kornberg A, Kupper B, Tannapfel A, et al: Patients with 18F-FDG non-avid advanced HCC on clinical staging may achieve recurrencefree long-term survival after liver transplantation. Liver Transplant 2011;18:53-61
73. Yang S, Suh K, Lee HW, et al: The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transplant 2006;12:1655-1660 (Pubitemid 44742545)
74. Lee J, Park J, Kim D, et al: Prognostic value of 18F-FDG-PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011;31:1144-1149
75. Shin DY, Han SW, Oh DY, et al: Prognostic implication of (18)F-FDGPET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 2011;68:165-175
76. Higashi T, Hatano E, Ikai I, et al: FDG-PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-482
77. Lee JW, Paeng JC, Kang KW, et al: Prediction of tumor recurrence by 18F-FDG-PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682-687
78. Hatano E, Ikai I, Higashi T, et al: Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736-1741 (Pubitemid 44411232)
79. Kim H, Kim J, Shin Y, et al: Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDGPET/CT. J Nucl Med 2011;51:1849-1856
80. Kim J, Seong J, Yun M, et al: Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:1172-1178
81. Cascales Campos P, Ramirez P, Gonzalez R, et al: Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: Initial results. Transplant Proc 2011;43:2213-2215
82. Dierckx R, Maes A, Peeters M, et al: FDG-PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 2009;53:336-342
83. Paudyal B, Oriuchi N, Paudyal P, et al: Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG-PET after radiofrequency ablation therapy. Oncol Rep 2007;18:1469-1473
84. Torizuka T, Tamaki N, Inokuma T, et al: Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969 (Pubitemid 24376612)
85. Han A, Gwak G, Choi M, et al: The clinical value of 18F-FDG-PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinoma. Hepato Gastroenterol 2009;56:1111-1116
86. Anderson GS, Brinkmann F, Soulen MC, et al: FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-197 (Pubitemid 38281975)
87. Chen YK, Hsieh DS, Liao CS, et al: Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005; 25:4719-4725
88. Yoon KT, Kim JK, Kim do Y, et al: Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007; 72(suppl 1):104-110 (Pubitemid 350256673)
89. Sugiyama M, Sakahara H, Torizuka T, et al: 18F-FDG-PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroeneterol 2004;39:961-968 (Pubitemid 39490173)
90. Lin CY, Chen JH, Liang JA, et al: 18F-FDG-PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Radiol 2011 Sep 5 [Epub ahead of print]
91. Jeng L, Changlai S, Shen Y, et al: Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003;50:2154-2156 (Pubitemid 37468015)
92. Lin WY, Tsai SC, Hung GU: Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005;26:315-321
93. Cheung T, Chan S, Ho C, et al: Can positron emission tomography with the dual tracers [11C]acetate and [18F]fluorodeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transplant 2011;17:1218-1225
94. Salem N, Kuang Y, Corn D, et al: [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol 2011;13:140-151
95. Ho CL, Yu SC, Yeung DW: 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-221
96. Ho CL, Chen S, Cheng TK, et al: PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology 2011;258:515-523
97. Ho CL, Chen S, Yeung DW, et al: Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-909 (Pubitemid 46909918)
98. Hwang K, Choi D, Lee S, et al: Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG-PET/CT: A preliminary study. Appl Radiat Isol 2009;67:1195-1198
99. Park JW, Kim JH, Kim SK, et al: A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-1921
100. Kuang Y, Salem N, Tian H, et al: Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]choline: Correlation with in vivo metabolic studies. J Nucl Med 2011;52:98-108
101. Yamamoto Y, Nishiyama Y, Kameyama R, et al: Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG-PET. J Nucl Med 2008;49:1245-1248
102. Talbot JN, Fartoux L, Balogova S, et al: Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010;51:1699-1706
103. Talbot JN, Gutman F, Fartoux L, et al: PET/CT in patients with hepatocellular carcinoma using 18F-fluorocholine: Preliminary comparison with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285-1289 (Pubitemid 44630783)